National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

doxorubicin-magnetic targeted carrier complex
A formulation of the anthracycline antibiotic doxorubicin in which doxorubicin is bound to microscopic beads of activated carbon and iron as a magnetic-targeted carrier (MTC). Doxorubicin, an intercalator and a topoisomerase II inhibitor, prevents DNA replication and ultimately inhibits protein synthesis. This agent also generates oxygen free radicals, resulting in cytotoxic lipid peroxidation of cell membrane lipids. Guided by the placement of a magnet on the body surface overlying a tumor site, the doxorubicin-MTC complex delivers doxorubicin directly to the tumor site, thereby targeting and prolonging the duration of doxorubicin-mediated cytotoxicity to the tumor bed while minimizing systemic toxicity. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Abbreviations:DOX-MTC
MTC-DOX



Previous:DOXIL, doxorubicin hydrochloride, doxorubicin prodrug INNO-206, doxorubicin-GnRH agonist conjugate AEZS-108, doxorubicin-HPMA conjugate
Next:doxycycline, dronabinol, droperidol, Droxia, DT(388)IL3 fusion protein

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov